Treatment-resistant Schizophrenia Clinical Trial
Official title:
A Pilot Randomized Controlled Study to Compare Avatar Therapy and Cognitive Behavioral Therapy in Patients With Treatment-resistant Schizophrenia.
Schizophrenia is associated with long-lasting health, social and financial burden for patients, families, caregivers and society. Unfortunately, 25-30% of schizophrenia patients respond poorly to antipsychotic medication. Moreover, psychotherapeutic treatment alternatives are very limited for this suffering population. This unmet clinical need requires innovation and action. Psychotherapeutic treatment alternatives such as Cognitive Behavior Therapy (CBT) provide at best moderate results. Using immersive virtual reality, we recently tested a novel psychotherapeutic intervention, Avatar Therapy (AT), where the therapist engages in a dialogue with the patient through a virtual representation of the patient's distressing voice. This approach, being both relational and experiential, provides a unique opportunity to aid patients gain control over their voice. The results of our pilot study on AT were clinically promising for the severity and distress related to hallucinations, positive symptomatology and emotion regulation. To further research in this field, the primary goal of this randomized-controlled, single-site parallel study is to show that AT is superior to CBT for the treatment of persistent auditory hallucinations in schizophrenia. Our secondary goal is to examine the effects of these interventions on emotion regulation, mood symptoms (anxiety and depression), self-esteem, level of functioning and quality of life.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03076346 -
Neural Biomarkers of Clozapine Response
|
||
| Completed |
NCT03148639 -
Virtual Reality Therapy for Treatment-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
| Recruiting |
NCT06270108 -
The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia
|
Early Phase 1 | |
| Not yet recruiting |
NCT06060886 -
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
|
Phase 4 | |
| Recruiting |
NCT05694000 -
Hippocampus DBS in Treatment-resistant Schizophrenia
|
N/A | |
| Completed |
NCT01105481 -
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients
|
Phase 4 | |
| Recruiting |
NCT02361554 -
Deep Brain Stimulation in Treatment Resistant Schizophrenia
|
N/A | |
| Recruiting |
NCT05299749 -
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
|
N/A | |
| Not yet recruiting |
NCT05259306 -
Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia
|
N/A | |
| Terminated |
NCT03230864 -
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
|
Phase 3 | |
| Recruiting |
NCT05337904 -
Deep Brain Stimulation Recovery in Treatment-Resistant Schizophrenia
|
N/A | |
| Terminated |
NCT03868839 -
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
|
Phase 2 | |
| Not yet recruiting |
NCT04528095 -
SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia
|
Phase 3 | |
| Not yet recruiting |
NCT06128408 -
The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset
|
||
| Recruiting |
NCT05074732 -
Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.
|
||
| Completed |
NCT03983018 -
Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
|
Phase 1 | |
| Recruiting |
NCT05741502 -
An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine
|
Phase 4 | |
| Recruiting |
NCT04054778 -
Comparaison of Avatar Therapy to Cognitive Behavioral Therapy in Schizophrenia With Treatment Refractory Hallucinations
|
N/A |